TScan cuts 75% of staff, pauses ALLOHA-2 to focus on in vivo solid tumor programSep 2Clinical readoutTScan Therapeutics, Inc.
TScan doses first patient in Phase 3 heme trial, cites Cohort C manufacturing dataAug 12Quarterly updateTScan Therapeutics, Inc.
TScan Therapeutics registers Phase 3 trial of TSC-101 for AML and MDS transplant patientsJul 14Trial updateTSC-101TScan Therapeutics, Inc.
Sign inSign in